Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belrestotug + dostarlimab + chemotherapy
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Belrestotug + dostarlimab + chemotherapy is a discontinued combination immunotherapy regimen previously studied for first-line treatment of advanced, PD-L1 high non-small cell lung cancer (NSCLC). Belrestotug is a human IgG1 monoclonal antibody targeting TIGIT (T cell immunoreceptor with Ig and ITIM domains), designed to enhance anti-tumor immunity by disrupting TIGIT-mediated immunosuppression. Dostarlimab (Jemperli) is an anti–PD-1 monoclonal antibody that facilitates immune activation against tumors. The regimen was intended to synergistically block two key immune checkpoint pathways (TIGIT and PD-1) alongside chemotherapy, aiming to improve response rates and durable benefit. Phase 2 trials (GALAXIES Lung-201) showed increased response rates but failed to improve progression-free survival, leading to global termination of the program due to lack of efficacy.
- Other names
- belrestotug + Jemperli + chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on belrestotug + dostarlimab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belrestotug + dostarlimab + chemotherapy.